Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium has accepted ranibizumab (Lucentis®) for restricted use within NHS Scotland for the treatment of adults with macular oedema secondary to central retinal vein occlusion (CRVO).
The Drug Advice discusses the evidence considered by the SMC (please see the link below for details). This notes that ranibizumab treatment was associated with significant improvements in visual acuity in one study of patients with branch retinal vein occlusion (BRVO) and in one study of patients with central retinal vein occlusion (CRVO).
The acceptance of ranibizumab for use in the treatment of CRVO takes into account a Patient Access Scheme (PAS) and the advice is contingent upon its continuing availability. The drug advice notes that the benefits seen in the clinical study were considerable and that there is a lack of alternative treatment options for this group of patients.
The SMC has not accepted the use of ...
Uncategorized